Validation of Relapse Risk Biomarkers for Routine Use in Patients With Juvenile Idiopathic Arthritis

Página do item simplificado
dc.contributor.authorRothmund, Friederike
dc.contributor.authorGerss, Joachim
dc.contributor.authorRuperto, Nicolino
dc.contributor.authorDaebritz, Jan
dc.contributor.authorWittkowski, Helmut
dc.contributor.authorFrosch, Michael
dc.contributor.authorWulffraat, Nico M.
dc.contributor.authorWedderburn, Lucy R.
dc.contributor.authorHolzinger, Dirk
dc.contributor.authorGohar, Faekah
dc.contributor.authorVastert, Sebastiaan J.
dc.contributor.authorBrik, Riva
dc.contributor.authorDeslandre, Chantal Job
dc.contributor.authorMelo-Gomes, Jose Antonio [UNESP]
dc.contributor.authorMagalhães, Cláudia Saad [UNESP]
dc.contributor.authorBarcellona, Roberto
dc.contributor.authorRusso, Ricardo
dc.contributor.authorGattorno, Marco
dc.contributor.authorMartini, Alberto
dc.contributor.authorRoth, Johannes
dc.contributor.authorFoell, Dirk
dc.contributor.authorPRINTO
dc.contributor.institutionUniv Childrens Hosp
dc.contributor.institutionUniv Munster
dc.contributor.institutionPaediat Rheumatol Int Trials Org
dc.contributor.institutionChildrens Hosp Datteln
dc.contributor.institutionWilhelmina Childrens Hosp
dc.contributor.institutionInst Child Hlth UCL
dc.contributor.institutionRambam Med Ctr
dc.contributor.institutionHop Cochin
dc.contributor.institutionInst Portugues Reumatol
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionAzienda Osped
dc.contributor.institutionHosp Pediat Juan P Garrahan
dc.contributor.institutionUniv Genoa
dc.date.accessioned2014-12-03T13:09:02Z
dc.date.available2014-12-03T13:09:02Z
dc.date.issued2014-06-01
dc.description.abstractObjective. The myeloid-related proteins 8 and 14 (MRP-8/MRP-14) and neutrophil-derived S100A12 are biomarkers of inflammation. They can be used to determine the relapse risk in patients with juvenile idiopathic arthritis (JIA) after stopping antiinflammatory treatment. In this study, we tested the performance of different enzyme-linked immunosorbent assays (ELISAs) in order to validate systems available for routine use.Methods. MRP-8/MRP-14 and S100A12 serum concentrations of 188 JIA patients in remission were analyzed. Commercially available test systems were compared to experimental ELISAs established in house. The ability of the assays to identify JIA patients at risk for relapse was analyzed.Results. For MRP-8/MRP-14, the PhiCal Calprotectin and Buhlmann MRP8/14 Calprotectin ELISAs revealed hazard ratios of 2.3 and 2.1, respectively. For S100A12, the CircuLex S100A12/EN-RAGE ELISA revealed a hazard ratio of 3.1. The commercial assays allowed a JIA relapse prediction that was at least comparable to the experimental ELISAs.Conclusion. For the prediction of JIA relapse after stopping medication, the biomarkers MRP-8/MRP-14 and S100A12 can be determined by using assays that are available for routine use. The tested commercial MRP-8/MRP-14 and S100A12 ELISAs showed a performance comparable to well-established experimental ELISA protocols when assay-specific cutoffs for the indication of relapse prediction are thoroughly applied.en
dc.description.affiliationUniv Childrens Hosp, Munster, Germany
dc.description.affiliationUniv Munster, D-48149 Munster, Germany
dc.description.affiliationPaediat Rheumatol Int Trials Org, Ist Giannina Gaslini, Genoa, Italy
dc.description.affiliationChildrens Hosp Datteln, Datteln, Germany
dc.description.affiliationWilhelmina Childrens Hosp, Utrecht, Netherlands
dc.description.affiliationInst Child Hlth UCL, London, England
dc.description.affiliationRambam Med Ctr, Haifa, Israel
dc.description.affiliationHop Cochin, Ctr Reference Natl Arthrites Juveniles, F-75674 Paris, France
dc.description.affiliationInst Portugues Reumatol, Lisbon, Portugal
dc.description.affiliationUNESP, Botucatu, SP, Brazil
dc.description.affiliationAzienda Osped, Sciacca, Ag, Italy
dc.description.affiliationHosp Pediat Juan P Garrahan, Buenos Aires, DF, Argentina
dc.description.affiliationUniv Genoa, Genoa, Italy
dc.description.affiliationUnespUNESP, Botucatu, SP, Brazil
dc.description.sponsorshipInterdisciplinary Centre of Clinical Research at the University of Munster (IZKF)
dc.description.sponsorshipSparks
dc.description.sponsorshipEuropean Union
dc.description.sponsorshipPRINTO (Paediatric Rheumatology International Trials Organisation)
dc.description.sponsorshipNovartis
dc.description.sponsorshipIdInterdisciplinary Centre of Clinical Research at the University of Munster (IZKF)CRA04
dc.description.sponsorshipIdSparks08ICH09
dc.description.sponsorshipIdEuropean UnionEC-GA 305266 MIAMI
dc.format.extent949-955
dc.identifierhttp://dx.doi.org/10.1002/acr.22248
dc.identifier.citationArthritis Care & Research. Hoboken: Wiley-blackwell, v. 66, n. 6, p. 949-955, 2014.
dc.identifier.doi10.1002/acr.22248
dc.identifier.issn2151-464X
dc.identifier.lattes7098310008371632
dc.identifier.orcid0000-0002-7631-7093
dc.identifier.urihttp://hdl.handle.net/11449/111852
dc.identifier.wosWOS:000337975700020
dc.language.isoeng
dc.publisherWiley-Blackwell
dc.relation.ispartofArthritis Care & Research
dc.relation.ispartofjcr4.149
dc.rights.accessRightsAcesso restrito
dc.sourceWeb of Science
dc.titleValidation of Relapse Risk Biomarkers for Routine Use in Patients With Juvenile Idiopathic Arthritisen
dc.typeArtigo
dcterms.licensehttp://olabout.wiley.com/WileyCDA/Section/id-406071.html
dcterms.rightsHolderWiley-Blackwell
unesp.author.lattes7098310008371632[15]
unesp.author.orcid0000-0002-1256-8483[17]
unesp.author.orcid0000-0003-4219-5283[4]
unesp.author.orcid0000-0002-7631-7093[15]
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Medicina, Botucatupt
Arquivos
Coleções
Artigos - Pediatria - FMB